Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 7/20 | 0.58 |
| ▸ | CTRC | Q99895 | 1/20 | 0.57 |
| ▸ | KMO | O15229 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1207020 | 0.88 | CTRC (0.51) | MCL1CTRCKMOALDH1A1SMN1; SMN2 | |
| SCHEMBL1201745 | 0.85 | CTRC (0.49) | MCL1CTRCKMOALDH1A1SMN1; SMN2 | |
| SCHEMBL16724450 | 0.82 | ALDH1A1 (0.54) | CTRCALDH1A1SMN1; SMN2HPGDKDM4E | |
| SCHEMBL316446 | 0.81 | MCL1 (0.81) | MCL1KMOADORA3ADORA1 | |
| SCHEMBL15383823 | 0.81 | MCL1 (0.65) | MCL1ALDH1A1SMN1; SMN2HPGDKDM4E | |
| SCHEMBL14886507 | 0.80 | MEN1 (0.67) | CTRCALDH1A1SMN1; SMN2MEN1HPGD | |
| SCHEMBL983902 | 0.80 | MCL1 (0.59) | MCL1CTRCKMOALDH1A1SMN1; SMN2 | |
| SCHEMBL1200252 | 0.79 | GABRA2 (0.55) | ALDH1A1SMN1; SMN2HPGDL3MBTL1KDM4E | |
| SCHEMBL744473 | 0.78 | ALOX15 (0.61) | MCL1KMOKDM4ELMNA | |
| SCHEMBL4265697 | 0.78 | KMO (0.58) | MCL1CTRCKMOALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081903-B1 | 2-AMINOCARBONYL-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2014-05-07 | — | — | EP | disclosed |
| CN-101522629-B | 2-aminocarbonyl-pyridine derivatives | ACTELION PHARMACEUTICALS LTD | 2012-07-18 | — | — | CN | disclosed |
| US-8093250-B2 | 2-aminocarbonyl-pyridine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-01-10 | — | — | US | disclosed |
| US-8058263-B2 | Substituted 2-phenyl-pyridine derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2011-11-15 | — | — | US | disclosed |
| US-8058263-B2 | Substituted 2-phenyl-pyridine derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2011-11-15 | — | — | US | disclosed |
| US-20110046089-A1 | SUBSTITUTED 2-PHENYL-PYRIDINE DERIVATIVES | VIATRIS ASIA PACIFIC PTE. LTD. (SG) | 2011-02-24 | — | — | US | disclosed |
| US-20110046089-A1 | SUBSTITUTED 2-PHENYL-PYRIDINE DERIVATIVES | VIATRIS ASIA PACIFIC PTE. LTD. (SG) | 2011-02-24 | — | — | US | disclosed |
| US-20100035895-A1 | 2-AMINOCARBONYL-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-02-11 | — | — | US | disclosed |
| WO-2009125366-A1 | SUBSTITUTED 2-PHENYL-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-10-15 | — | — | WO | disclosed |
| CN-101522629-A | 2-aminocarbonyl-pyridine derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-02 | — | — | CN | disclosed |
| EP-2081903-A2 | 2-AMINOCARBONYL-PYRIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2009-07-29 | — | — | EP | disclosed |
| US-20090048258-A1 | Amide Compound | TAKEDA, PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-19 | — | — | US | disclosed |
| WO-2008044217-A2 | 2-AMINOCARBONYL-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-04-17 | — | — | WO | disclosed |
| EP-1845081-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035895-A1 | 2-AMINOCARBONYL-PYRIDINE DERIVATIVES | P2RY12, P2RY2, P2RY1 | MCL1 3193/4885CTRC 4029/4885KMO 933/4885 |
| US-20110046089-A1 | SUBSTITUTED 2-PHENYL-PYRIDINE DERIVATIVES | P2RY12, P2RY13, P2RY11 | MCL1 2710/4885CTRC 3463/4885KMO 1354/4885 |
| US-20090048258-A1 | Amide Compound | DLAT, DGAT1, DGAT2 | MCL1 3227/4885CTRC 4808/4885KMO 3705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.